BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu C, Chen P, Lai M, Kao J, Chen D. Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. J Med Virol 2004;74:237-45. [DOI: 10.1002/jmv.20176] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Tada T, Kumada T, Toyoda H, Ohisa M, Akita T, Tanaka J. Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model. J Gastroenterol 2018;53:1196-205. [PMID: 29675604 DOI: 10.1007/s00535-018-1467-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
2 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liu G, Lao R, Xu L, Xu Q, Li L, Zhang M, Song S, Fan C. Single-nucleotide polymorphism genotyping using a novel multiplexed electrochemical biosensor with nonfoulingsurface. Biosensors and Bioelectronics 2013;42:516-21. [DOI: 10.1016/j.bios.2012.11.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
4 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Tanaka J. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic: HCC development in CHB during NA therapy. Journal of Gastroenterology and Hepatology 2017;32:451-8. [DOI: 10.1111/jgh.13473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
5 Liu CJ, Chen PJ, Lai MY, Lin FY, Wang T, Kao JH, Chen DS. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int. 2006;26:949-955. [PMID: 16953835 DOI: 10.1111/j.1478-3231.2006.01319.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
6 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabtake S, Ito T. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy. J Gastroenterol 2015;50:795-804. [DOI: 10.1007/s00535-014-1011-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427-433. [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
8 Elizalde MM, Campos RH, Barbini L. X protein variants of the autochthonous Latin American hepatitis B virus F genotype promotes human hepatocyte death by the induction of apoptosis and autophagy. Virus Res 2017;242:156-65. [PMID: 28986109 DOI: 10.1016/j.virusres.2017.09.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tsai KN, Ou JJ. Hepatitis B virus e antigen and viral persistence. Curr Opin Virol 2021;51:158-63. [PMID: 34717215 DOI: 10.1016/j.coviro.2021.10.003] [Reference Citation Analysis]
10 Yuan H, Ka-ho Wong D, Doutreloigne J, Sablon E, Lai C, Yuen M. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. Journal of Infection 2007;54:497-503. [DOI: 10.1016/j.jinf.2006.08.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
11 Streinu-Cercel O, Streinu-Cercel A, Preoţescu LL, Streinu-Cercel A. Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. Germs 2012;2:18-22. [PMID: 24432259 DOI: 10.11599/germs.2012.1009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
12 Wu HL, Kao JH, Chen TC, Wu WH, Liu CH, Su TH, Yang HC, Chen DS, Chen PJ, Liu CJ. Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications. J Gastroenterol Hepatol 2014;29:1629-36. [PMID: 24730549 DOI: 10.1111/jgh.12606] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
13 Tian Y, Kuo CF, Akbari O, Ou JH. Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission. Immunity. 2016;44:1204-1214. [PMID: 27156385 DOI: 10.1016/j.immuni.2016.04.008] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 17.0] [Reference Citation Analysis]
14 Wu S, Imazeki F, Kurbanov F, Fukai K, Arai M, Kanda T, Yonemitsu Y, Tanaka Y, Mizokami M, Yokosuka O. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. J Hepatol 2011;54:19-25. [PMID: 20932594 DOI: 10.1016/j.jhep.2010.06.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
15 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. Eur J Gastroenterol Hepatol 2019;31:1452-9. [PMID: 31082998 DOI: 10.1097/MEG.0000000000001434] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, Tanaka J. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol. 2018;33:918-925. [PMID: 28914957 DOI: 10.1111/jgh.13989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
17 Ke WM, Li XJ, Yu LN, Lai J, Li XH, Gao ZL, Chen PJ. Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China. J Gastroenterol. 2006;41:347-351. [PMID: 16741614 DOI: 10.1007/s00535-005-1781-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
18 Elizalde MM, Sevic I, González López Ledesma MM, Campos RH, Barbini L, Flichman DM. Human hepatocytes apoptosis induced by replication of hepatitis B virus subgenotypes F1b and F4: Role of basal core promoter and preCore mutations. Virology 2018;513:160-7. [DOI: 10.1016/j.virol.2017.10.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. Journal of Hepatology 2016;65:48-56. [DOI: 10.1016/j.jhep.2016.03.013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 15.0] [Reference Citation Analysis]
20 Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 2015;13:2071-2087.e16. [DOI: 10.1016/j.cgh.2015.07.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 12.2] [Reference Citation Analysis]